Human Genome Shares Fall On Lazard Analyst Outlook

He also echoed sentiments of other analysts, calling lupus a difficult disease to treat. Lupus is a chronic disease where the immune system attacks the body's own tissue. On Thursday Leerink Swann Research analyst reaffirmed a "Outperform"rating on the stock, saying the recent study data bodes well for future results. Still, he only gave the drug a 60 percent chance of success.

Benlysta was previously called LymphoStat-B, and is being developed through a partnership between Rockville, Md.-based Human Genome Sciences and British drug maker GlaxoSmithKline PLC.

Meanwhile, Flynn took a cautious view on the company's hepatitis C drug candidate Albuferon, citing tough competition in that market.